1 / 7

Goals

www.shaanlibby.com. The Team. Founder:Shaan Katari LibbyAssociates:Formerly with large venturesDr. Cori GormanKate GunningUniversity researchersDr. Ken KengatharanDr. Jim Libby. Marketing / BusinessAnthony StolisDavid OliverAudrey ErbesVenture capitalist Chris E. PiercyGene therap

sadah
Download Presentation

Goals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    2. www.shaanlibby.com Goals To help companies develop business connections in international markets. Special emphasis on: USA, UK, India Strategic Services Networking Services Grants / application processes Corporate identity Strategic services: Market research capability Venture capital access Sound experience from Shaan Libby’s most recent role as Vice Consul (Trade). Utilizing excellent network of associate consultants all physically based in the US Networking services: Essential to your business in order to grow Making connections for you Facilitating introductions/ meetings Obtaining speaker spots for you at conferences Arranging speaker meetings Expedite executive recruitment We can advise on DTI /US research grants that would be open to you Paperwork to assist you with the application process Help you by conducting physical meetings if you are interested in India – partnering or sub-contracting research/trials Strategic services: Market research capability Venture capital access Sound experience from Shaan Libby’s most recent role as Vice Consul (Trade). Utilizing excellent network of associate consultants all physically based in the US Networking services: Essential to your business in order to grow Making connections for you Facilitating introductions/ meetings Obtaining speaker spots for you at conferences Arranging speaker meetings Expedite executive recruitment We can advise on DTI /US research grants that would be open to you Paperwork to assist you with the application process Help you by conducting physical meetings if you are interested in India – partnering or sub-contracting research/trials

    3. www.shaanlibby.com The Team Founder: Shaan Katari Libby Associates: Formerly with large ventures Dr. Cori Gorman Kate Gunning University researchers Dr. Ken Kengatharan Dr. Jim Libby Marketing / Business Anthony Stolis David Oliver Audrey Erbes Venture capitalist Chris E. Piercy Gene therapy Dr. Nathan Bach New Associates coming on board in India… All the associate consultants are available on a project basis if appropriate.All the associate consultants are available on a project basis if appropriate.

    4. www.shaanlibby.com Current Clients include… Caretek Medical - Needlefree drug delivery technology 'Shaan Libby has been working with us since mid-July 2005.  We asked her to use her US biopharma contacts to help open doors for us into a number of pharmaceutical and biotehnology companies.  Of the 9 top- tier companies targeted, we have now got direct access to 5, with 1 telephone meeting already conducted, and 4 in-person meetings arranged for early October.  We have also received some useful feedback regarding our technology.  We are pleased, and hope to continue exploring the US market, and possibly look at other markets / services on offer from Shaan.  I would say that on the whole Shaan has saved us time and effort, and has provided good value for money.'    - Dr.Charles Potter, CEO, Caretek Medical (Oxford). Caretek Medical - Needlefree transdermal drug delivery technology - ImplaJect® that pushes a pharmaceutical formulation in a solid, semi-solid or liquid form directly through the skin of a human or animal using the needleless, spring powered, ImplaJect® device. Meetings have been successfully arranged for them with top-tier US Biopharma companies, and work ongoing. Scancell- Developing products that stimulate the immune system to treat or prevent cancer. They have four therapeutic antibodies and two cancer vaccines in development, based upon their proprietary ImmunoBody® technology. Exploring international markets; work underway. Caretek Medical - Needlefree transdermal drug delivery technology - ImplaJect® that pushes a pharmaceutical formulation in a solid, semi-solid or liquid form directly through the skin of a human or animal using the needleless, spring powered, ImplaJect® device. Meetings have been successfully arranged for them with top-tier US Biopharma companies, and work ongoing. Scancell- Developing products that stimulate the immune system to treat or prevent cancer. They have four therapeutic antibodies and two cancer vaccines in development, based upon their proprietary ImmunoBody® technology. Exploring international markets; work underway.

    5. www.shaanlibby.com Scancell- therapeutic antibodies and cancer vaccines Feb ’06: Helped secure an EMDA grant for them (Research grant) worth 100K. ‘We have worked with Shaan Libby on a number of projects and have always found her to be pro-active, extremely willing, supportive and efficient.  I would particularly recommend her for anyone seeking to build networks within the US and India.’ -Dr Mike Capaldi, CEO, Scancell (Nottingham) Shaan Libby & Associates

    6. www.shaanlibby.com Thank you & Contact details shaan@shaanlibby.com (01865) 427 639 (0)7932 394 232 www.shaanlibby.com Oxford, England 1. Jonathan, please could you describe for us the FIND programme run by Genentech, and tell us how successful you feel it has been to date?   2.  Ideally, what should a small / medium-sized company do to get onto your radar screen?   3.  How early could Genentech get involved with technology that might be of interest?  Could it still be within a University's research lab?   4.  Jonathan, please would you mention a couple of recent successful collaborations with UK companies?  Also, were there areas that could have been smoother?  1. Jonathan, please could you describe for us the FIND programme run by Genentech, and tell us how successful you feel it has been to date?   2.  Ideally, what should a small / medium-sized company do to get onto your radar screen?   3.  How early could Genentech get involved with technology that might be of interest?  Could it still be within a University's research lab?   4.  Jonathan, please would you mention a couple of recent successful collaborations with UK companies?  Also, were there areas that could have been smoother?  

    7. www.shaanlibby.com Today’s panel: Julie Crane (Finance South East Limited) Dr.Matthew Frohn, Director of Seed Capital (Oxford Venture Capital Trust) Tara Lambert, Manager, Business Grants (SEEDA) James Mallinson, Portfolio Manager (Isis Innovation Ltd.) Marcus O’Neill (GE HFS Life Science Finance) Dr.Jonathan Lewis Dr.Jonathan Lewis has worked at Genentech since the year 2000.  He is Associate Director for Business Development at Genentech.  As a member of the Business Development team, he is responsible for worldwide partnering activities including technology access deals, in-licensing of early and late-stage therapeutics, and out-licensing of Genentech development projects. Prior to Business Development, he was a member of the New Product Market Planning group with responsibility for strategic assessments and lifecycle planning within the immune related diseases franchise. Jonathan worked in Investment banking with Credit Suisse First Boston in London after having received his D.Phil. in Immunology from Oxford. Dr.Jonathan Lewis Dr.Jonathan Lewis has worked at Genentech since the year 2000.  He is Associate Director for Business Development at Genentech.  As a member of the Business Development team, he is responsible for worldwide partnering activities including technology access deals, in-licensing of early and late-stage therapeutics, and out-licensing of Genentech development projects. Prior to Business Development, he was a member of the New Product Market Planning group with responsibility for strategic assessments and lifecycle planning within the immune related diseases franchise. Jonathan worked in Investment banking with Credit Suisse First Boston in London after having received his D.Phil. in Immunology from Oxford.

More Related